All In Biotech

Drug Trial Radar · NCT05163808

A Randomized Study of BPN14770 in Male Adolescents (Aged 9 to < 18 Years) With Fragile X Syndrome

A Randomized, Double-blind, Placebo-controlled, Two-Part Study of BPN14770 in Male Adolescents (Aged 9 to < 18 Years) With Fragile X Syndrome

Last checked: Nov 19, 2026Latest source record: Aug 31, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 163 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

163

Actual

Start

Mar 29, 2022

Primary completion

Sep 2, 2025

Study completion Sep 2, 2025

Sponsor

Lead sponsor
Tetra Discovery PartnersIndustry
Sponsor type
Industry
First posted
Dec 20, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 9 years, up to 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a 2-part study, with each part having a unique set of objectives for male adolescents aged 9 to \< 18 years with fragile X syndrome (FXS). Part 1 is an open-label, single-dose, pharmacokinetics (PK) assessment of BPN14770 25 mg and 50 mg, while Part 2 is double-blind (DB) and randomized between two treatment groups (Study Drug and Placebo).

Conditions

  • Fragile X Syndrome

Interventions

  • zatolmilastDrug

    Subjects will receive a 15 mg or 25 mg dose of zatolmilast (BPN14770) or placebo

  • PlaceboDrug

    Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. NIH Toolbox Cognitive Battery cognition crystallized composite scoreTime frame: 13 Weeks

Locations

17 sites in 1 country. Site status is shown where the registry gives one.

  • Amnova Clinical Research

    Irvine, California

  • Thompson Autism & Neurodevelopment Center - CHOC

    Orange, California

  • UC Davis

    Sacramento, California

  • Children's Hospital Colorado

    Aurora, Colorado

  • University of Miami

    Miami, Florida

  • Emory University School of Medicine

    Atlanta, Georgia

  • Rush University Medical Center

    Chicago, Illinois

  • University of Kansas Medical Center

    Kansas City, Kansas

  • Kennedy Krieger Institute

    Baltimore, Maryland

  • Boston Children's Hospital

    Boston, Massachusetts

  • U Mass

    Worcester, Massachusetts

  • Icahn School of Medicine at Mount Sinai Hospital

    New York, New York

  • Cincinatti Children's Hospital Medical Center

    Cincinnati, Ohio

  • Suburban Research Associates

    Media, Pennsylvania

  • Clinic for Special Children

    Strasburg, Pennsylvania

  • Greenwood Genetic Center

    Greenville, South Carolina

  • University of Utah and Primary Childrens Hospital

    Salt Lake City, Utah

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.